AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00736944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
Study NCT00736944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma volume
Description: For patients designated as Bleeding, where International Normalized Ratio (INR) > 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets volume
Description: For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelets volume
Description: For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study NCT01306695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Description: The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease.
Study NCT01306695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community Health Worker (CHW) Case Management
Description: The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
Study NCT03655847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
Study NCT03969173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP3
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
Study NCT03969173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP6
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
Study NCT00887146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study NCT03969173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: applying PEEP9
Description: The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
Study NCT00887146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine
Description: Days 8-21: 60 mg/m\^2 orally
Study NCT00887146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant temozolomide (TMZ)
Description: 150 or 200 mg/m\^2 orally
Study NCT00887146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCNU
Description: Day 1: 110 mg/m\^2 orally
Study NCT01219257 — intervention group
Intervention type: BIOLOGICAL
Intervention: Anti-TNF alpha therapy
Description: All medical treatment will be standardizes following good medical practice
Study NCT01286597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary restriction
Description: restrict intake of lactose
Study NCT02803905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Islet transplantation
Description: This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
Study NCT02803905 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Islet transplantation
Description: This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
Study NCT02273089 — intervention group
Intervention type: DEVICE
Intervention: CPAP (ResMed S9 AutoSet)
Description: nocturnal CPAP for three months
Study NCT01957865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed SMS, real-time monitoring
Description: SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
Study NCT01957865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triggered SMS, real-time monitoring
Description: SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
Study NCT00887146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Days 8 and 29: 1.4 mg/m\^2 IV
Study NCT04202718 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VitalPatch Device
Description: The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
Study NCT04389398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pocket compression fixation belt
Description: Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
Study NCT04389398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pocket compression fixation belt
Description: Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
Study NCT02222389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for Alcohol
Description: Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
Study NCT02222389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for drugs
Description: Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
Study NCT02222389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM for both substances
Description: Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize.
Study NCT02222389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Contingent group
Description: Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
Study NCT01830738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port, peri-umbilical hysterectomy
Description: Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
Study NCT01830738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port hysterectomy
Description: Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
Study NCT01983371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
Study NCT01983371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
Study NCT03702647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30mL of 0.2% Ropivacaine placed in the POEM tunnel
Study NCT03702647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 30mL of normal saline placed in the POEM tunnel
Study NCT01592448 — intervention group
Intervention type: BEHAVIORAL
Intervention: Active Ingredient Icon
Description: Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen.
Study NCT00736944 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (Post induction)
Description: Monday-Friday, weeks 1-7
Study NCT00736944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
Study NCT00736944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: (Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
Study NCT03892187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Walking prescriptions plus weekly coaching calls prior to surgery.
Study NCT02340221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
Study NCT02549573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APOKYN
Description: Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
Study NCT02549573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All subjects will participate in a standardized PT intervention
Study NCT03750955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaque induced gingivitis
Description: Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
Study NCT03750955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene maintenance
Description: Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
Study NCT02549573 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Therapy
Description: All subjects will participate in a standardized PT intervention
Study NCT03297671 — intervention group
Intervention type: DRUG
Intervention: RhIg prophylaxis
Description: Two RhIg prophylaxis injections for Rh negative women
Study NCT03297671 — intervention group
Intervention type: DEVICE
Intervention: ELDONCARD
Description: ELDONCARD point-of-care test.
Study NCT03297671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELDONCARD Test
Description: LHVs will perform ELDONCARD test.
Study NCT04251091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
Study NCT04251091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Walking
Description: Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
Study NCT02970435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Discharge Instructions
Description: The video discharge instructions, will be provided to the patient at the time of surgical procedure.
Study NCT02970435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecommunication Reminders
Description: Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
Study NCT02970435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care: verbal and written discharge instructions for patients after surgery
Study NCT02970435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care: verbal and written discharge instructions for patients after surgery
Study NCT03736187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
Study NCT01330667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutramigen Infant Formula
Description: Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
Study NCT04210505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Topical Ointment
Description: Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
Study NCT02443935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: 60 mg s.c. twice weekly for 4 weeks
Study NCT02443935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: 60 mg s.c. twice weekly for 24 weeks
Study NCT04005300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard enteral nutrition
Description: Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
Study NCT04005300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: restricted enteral nutrition
Description: Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
Study NCT03701243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mNT-BBAVF
Description: Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
Study NCT03701243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCAVF
Description: Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
Study NCT03961308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT03961308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT03537443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
Study NCT03537443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
Study NCT00822380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: Daily 20mg of ferrous sulfate in liquid solution during 4 months
Study NCT00822380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplement
Description: Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
Study NCT00822380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient fortified porridge powder
Description: Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
Study NCT00822380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and ascorbic acid fortified water
Description: A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
Study NCT00822380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid supplement
Description: Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
Study NCT02351089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsules placebo
Description: Capsules
Study NCT02351089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules probiotic powder and corn starch
Study NCT04509258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
Study NCT04509258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: acetyl L-carnitine
Description: Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care